Glycemic control
Trials are small and concentrated in people who were deficient to start with, and the effect shrinks as the methods get better.
Not yet investigated
Trials are small and concentrated in people who were deficient to start with, and the effect shrinks as the methods get better.
This star is on the map because the show intends to take the question apart properly — the trials, how it is actually tested, whether the thing sold is the thing studied. That work is not done yet, and nothing here should be read as a conclusion. When the investigation is published it will appear on this page.
What we are reading
Gathered for the investigation and not yet written up. Each note says what the paper does and does not show.
28 RCTs. Every glycaemic index moved: fasting glucose -19.0 mg/dl, insulin -12.35 pmol/l, HbA1c -0.71%, HOMA-IR -1.53. Then read the heterogeneity: I-squared is 99.8% for fasting glucose and 89.9% for HOMA-IR. At 99.8% the trials are not estimating the same quantity, and a pooled mean across them is close to meaningless — the honest statement is that SOME chromium trials show large effects, not that chromium lowers glucose by 19 mg/dl. This is the single most important caveat on the node, and it is the sort of thing supplement marketing quotes without.
Connected on the map
Also in Glycemic control
The letter
The full citation list for each investigation, the studies that didn't make the episode, and any corrections — sent the morning it publishes.
No sponsors · No supplement affiliates · Unsubscribe any time
